glp 1 polycystic kidney disease Use of Anti-Diabetic Agents in Non-Diabetic Disease: From Bench to Bedside The Role of Glp-1 Receptor
Description
Leave-one-out sensitivity analyses confirmed the direction and magnitude of the AUD finding but highlighted the limited evidence base for hospitalization
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), initially developed for the treatment of type 2 diabetes and obesity, may modulate pathways associated with the hallmarks of aging
Bruising after semaglutide shots is common but preventable
Coverage and access policies that treat obesity as the chronic disease it is
Constantly thinking about when I could eat again
Long-term GLP-1 strategies, microdosing GLP-1 for maintenance to keep the weight off for good.
